Navigation

Aurorix

Aurorix - General Information

A reversible inhibitor of monoamine oxidase type A; (RIMA); (see monoamine oxidase inhibitors) that has antidepressive properties.

 

Pharmacology of Aurorix

Aurorix belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.

 

Additional information about Aurorix

Aurorix Indication: For the treatment of depression.
Mechanism Of Action: The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
Drug Interactions: Amitriptyline Possible severe adverse reaction with this combination
Amoxapine Possible severe adverse reaction with this combination
Clomipramine Possible severe adverse reaction with this combination
Cimetidine Cimetidine increases the effect of moclobemide
Desipramine Possible severe adverse reaction with this combination
Doxepin Possible severe adverse reaction with this combination
Imipramine Possible severe adverse reaction with this combination
Nortriptyline Possible severe adverse reaction with this combination
Paroxetine Possible severe adverse reaction with this combination
Protriptyline Possible severe adverse reaction with this combination
Tryptophanyl-5'amp Possible severe adverse reaction with this combination
Trimipramine Possible severe adverse reaction with this combination
Sertraline Possible severe adverse reaction with this combination
Citalopram Possible serotoninergic syndrome
Fluoxetine Risk of serotoninergic syndrome
Selegiline Decrease in selectivity
Sibutramine Possible serotoninergic syndrome with this combination
Tramadol Increased risk of seizures and serotonin syndrome
Dobutamine Aurorix increases the sympathomimetic effect
Dopamine Aurorix increases the sympathomimetic effect
Ephedra Aurorix increases the sympathomimetic effect
Ephedrine Aurorix increases the sympathomimetic effect
Epinephrine Aurorix increases the sympathomimetic effect
Fenoterol Aurorix increases the sympathomimetic effect
Norepinephrine Aurorix increases the sympathomimetic effect
Pseudoephedrine Aurorix increases the sympathomimetic effect
Salbutamol Aurorix increases the sympathomimetic effect
Phenylephrine Aurorix increases the sympathomimetic effect
Procaterol Aurorix increases the sympathomimetic effect
Pirbuterol Aurorix increases the sympathomimetic effect
Phenylpropanolamine Aurorix increases the sympathomimetic effect
Isoproterenol Aurorix increases the sympathomimetic effect
Mephentermine Aurorix increases the sympathomimetic effect
Metaraminol Aurorix increases the sympathomimetic effect
Methoxamine Aurorix increases the sympathomimetic effect
Orciprenaline Aurorix increases the sympathomimetic effect
Terbutaline Aurorix increases the sympathomimetic effect
Tramadol Increased risk of seizures and serotonin syndrome
Dextromethorphan Increased CNS toxicity
Meperidine Increased CNS toxicity (can cause death)
Donepezil Possible antagonism of action
Galantamine Possible antagonism of action
Rivastigmine Possible antagonism of action
Fluvoxamine Increased incidence of adverse effects with this association
Rizatriptan The MAO inhibitor increases the effect and toxicity of rizatriptan
Food Interactions: Not Available
Generic Name: Moclobemide
Synonyms: Moclobemida [Inn-Spanish]; Moclobemide [Usan-Ban-Inn]; Moclobemidum [Inn-Latin]; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclamine; Moclamide; Moclobemid; Moclaime; p-Chloro-N-(2-morpholinoethyl)benzamide
Drug Category: Antidepressive Agents; Monoamine Oxidase Inhibitors
Drug Type: Small Molecule; Approved; Investigational
Other Brand Names containing Moclobemide: Aurorix; Manerix;
Absorption: Well absorbed from the gastrointestinal tract. The presence of food reduces the rate but not the extent of absorption. Absolute bioavailability ranges from approximately 55% following administration of single doses of moclobemide to 90% following multiple dosing, due to the hepatic first pass effect.
Toxicity (Overdose): LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg
Protein Binding: Approximately 50% (primarily to albumin)
Biotransformation: Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
Half Life: 1.5 hours (4 hours in cirrhotic patients)
Dosage Forms of Aurorix: Tablet Oral
Tablet Oral
Chemical IUPAC Name: 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Chemical Formula: C13H17ClN2O2
Moclobemide on Wikipedia: http://en.wikipedia.org/wiki/Moclobemide
Organisms Affected: Humans and other mammals